RU2010136040A - Композиции, способные синергично вызывать посттранскрипционный сайленсинг экспрессии генов, и способы их применения - Google Patents
Композиции, способные синергично вызывать посттранскрипционный сайленсинг экспрессии генов, и способы их применения Download PDFInfo
- Publication number
- RU2010136040A RU2010136040A RU2010136040/10A RU2010136040A RU2010136040A RU 2010136040 A RU2010136040 A RU 2010136040A RU 2010136040/10 A RU2010136040/10 A RU 2010136040/10A RU 2010136040 A RU2010136040 A RU 2010136040A RU 2010136040 A RU2010136040 A RU 2010136040A
- Authority
- RU
- Russia
- Prior art keywords
- mrna
- target
- polynucleotide
- silencing
- component
- Prior art date
Links
- 230000030279 gene silencing Effects 0.000 title claims abstract 19
- 239000000203 mixture Substances 0.000 title claims abstract 15
- 230000014509 gene expression Effects 0.000 title claims abstract 10
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000013518 transcription Methods 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 claims abstract 42
- 108091033319 polynucleotide Proteins 0.000 claims abstract 24
- 102000040430 polynucleotide Human genes 0.000 claims abstract 24
- 239000002157 polynucleotide Substances 0.000 claims abstract 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract 12
- 108091026838 U1 spliceosomal RNA Proteins 0.000 claims abstract 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract 10
- 239000004055 small Interfering RNA Substances 0.000 claims abstract 10
- 108091035707 Consensus sequence Proteins 0.000 claims abstract 7
- 238000001727 in vivo Methods 0.000 claims abstract 7
- 230000001939 inductive effect Effects 0.000 claims abstract 5
- 239000013598 vector Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000002458 infectious effect Effects 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 241000710929 Alphavirus Species 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012226 gene silencing method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001323 posttranslational effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200800222 | 2008-01-29 | ||
| ES200800222 | 2008-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010136040A true RU2010136040A (ru) | 2012-03-10 |
Family
ID=40807539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010136040/10A RU2010136040A (ru) | 2008-01-29 | 2009-01-29 | Композиции, способные синергично вызывать посттранскрипционный сайленсинг экспрессии генов, и способы их применения |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110030075A1 (enExample) |
| EP (1) | EP2246432A2 (enExample) |
| JP (1) | JP2011510647A (enExample) |
| CN (1) | CN101981189A (enExample) |
| AU (1) | AU2009209571A1 (enExample) |
| BR (1) | BRPI0906657A2 (enExample) |
| CA (1) | CA2713458A1 (enExample) |
| MX (1) | MX2010008326A (enExample) |
| RU (1) | RU2010136040A (enExample) |
| WO (1) | WO2009095517A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2651493C2 (ru) * | 2013-09-30 | 2018-04-19 | Солювентис Гмбх | NOTCH 1-СПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ миРНК |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9441221B2 (en) | 2007-03-30 | 2016-09-13 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| US8343941B2 (en) | 2007-03-30 | 2013-01-01 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| US8907075B2 (en) | 2007-03-30 | 2014-12-09 | Samuel Ian Gunderson | Compositions and methods for gene silencing |
| WO2012045894A1 (es) * | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
| US9862945B2 (en) * | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
| CN107746857B (zh) * | 2017-08-07 | 2021-02-05 | 中国农业大学 | 一种抑制基因表达的rna干扰方法 |
| CN108893487A (zh) * | 2018-07-19 | 2018-11-27 | 中国农业科学院北京畜牧兽医研究所 | 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法 |
| JP2022524383A (ja) * | 2019-03-08 | 2022-05-02 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | ハンチントン病を処置するための組成物および方法 |
| EP4004204A1 (en) | 2019-07-23 | 2022-06-01 | Oxford BioMedica (UK) Limited | Enhancing production of lentiviral vectors |
| CN114159459A (zh) * | 2021-12-20 | 2022-03-11 | 塔里木大学 | miR-26a在制备治疗子宫内膜炎的药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6692910B2 (en) | 1997-07-28 | 2004-02-17 | The University Of Connecticut | Inhibition of a target messenger RNA with a modified U1 small nuclear RNA |
| EP1384784A1 (en) * | 2001-03-30 | 2004-01-28 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Method for reversible inhibition of gene expression by modified ribonucleoproteins |
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| CA2524569C (en) | 2002-05-03 | 2013-10-22 | Duke University | A method of regulating gene expression |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| PT3272872T (pt) | 2005-10-20 | 2020-06-26 | Uniqure Ip Bv | Vetores aav melhorados produzidos em células de insetos |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
| GB0701722D0 (en) * | 2007-01-30 | 2007-03-07 | Scottish Crop Res Inst | Inhibition of gene expression |
-
2009
- 2009-01-29 WO PCT/ES2009/000045 patent/WO2009095517A2/es not_active Ceased
- 2009-01-29 AU AU2009209571A patent/AU2009209571A1/en not_active Abandoned
- 2009-01-29 EP EP09705069A patent/EP2246432A2/en not_active Withdrawn
- 2009-01-29 CN CN2009801118031A patent/CN101981189A/zh active Pending
- 2009-01-29 US US12/865,046 patent/US20110030075A1/en not_active Abandoned
- 2009-01-29 JP JP2010544739A patent/JP2011510647A/ja active Pending
- 2009-01-29 RU RU2010136040/10A patent/RU2010136040A/ru not_active Application Discontinuation
- 2009-01-29 BR BRPI0906657-8A patent/BRPI0906657A2/pt not_active IP Right Cessation
- 2009-01-29 MX MX2010008326A patent/MX2010008326A/es not_active Application Discontinuation
- 2009-01-29 CA CA2713458A patent/CA2713458A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2651493C2 (ru) * | 2013-09-30 | 2018-04-19 | Солювентис Гмбх | NOTCH 1-СПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ миРНК |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010008326A (es) | 2010-08-18 |
| JP2011510647A (ja) | 2011-04-07 |
| EP2246432A2 (en) | 2010-11-03 |
| US20110030075A1 (en) | 2011-02-03 |
| WO2009095517A3 (es) | 2009-09-24 |
| CA2713458A1 (en) | 2009-08-06 |
| AU2009209571A1 (en) | 2009-08-06 |
| BRPI0906657A2 (pt) | 2015-07-14 |
| CN101981189A (zh) | 2011-02-23 |
| WO2009095517A2 (es) | 2009-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510647A5 (enExample) | ||
| Pirollo et al. | Antisense therapeutics: from theory to clinical practice | |
| Bian et al. | Hotair facilitates hepatic stellate cells activation and fibrogenesis in the liver | |
| Arango et al. | Dietary apigenin reduces LPS‐induced expression of miR‐155 restoring immune balance during inflammation | |
| WO2007134014A3 (en) | Compounds and methods for modulating expression of gcgr | |
| CY1111755T1 (el) | Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο | |
| JP2018519835A5 (enExample) | ||
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| DK2484365T3 (da) | Sammensætninger og fremgangsmåde til behandling af neovaskulære sygdomme | |
| Nageshwaran et al. | Epigenetics and triplet-repeat neurological diseases | |
| Zeybel et al. | Epigenetic modifications as new targets for liver disease therapies | |
| WO2006102461A3 (en) | Influenza therapeutic | |
| DK1706489T3 (da) | Oligomer forbindelser for modulationen af BCL-2 | |
| CY1108944T1 (el) | Θεραπευτικη χρηση των tgf-βητα2 αντινοηματικων ολιγονουκλεοτιδιων | |
| JP2012505657A5 (enExample) | ||
| JP2020510827A5 (enExample) | ||
| MX2010008326A (es) | Metodo y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresion genica de forma sinergica. | |
| Deng et al. | MicroRNA‐130a regulates neurological deficit and angiogenesis in rats with ischaemic stroke by targeting XIAP | |
| Xi et al. | Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice | |
| Dreieicher et al. | Nitric oxide inhibits glomerular TGF-β signaling via SMOC-1 | |
| Lee et al. | Interferon-γ suppresses activin A/NF-E2 induction of erythroid gene expression through the NF-κB/c-Jun pathway | |
| DK1587828T3 (da) | Defensivproteiner | |
| Song et al. | Lnc-DARVR/miR-365-1-5p/LAMB1 axis regulates rotavirus replication via the complement C3 pathway | |
| MX2007011665A (es) | Terapeutico para influenza. | |
| JP2007517498A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130517 |